- Home
- CPRI vs NVCR Comparison
CPRI vs NVCR Comparison
Compare CPRI & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRI
- NVCR
- Stock Information
- Founded
- CPRI 1981
- NVCR 2000
- Country
- CPRI United Kingdom
- NVCR Switzerland
- Employees
- CPRI N/A
- NVCR N/A
- Industry
- CPRI Apparel
- NVCR Medical/Dental Instruments
- Sector
- CPRI Consumer Discretionary
- NVCR Health Care
- Exchange
- CPRI Nasdaq
- NVCR Nasdaq
- Market Cap
- CPRI 2.5B
- NVCR 2.3B
- IPO Year
- CPRI 2011
- NVCR 2015
- Fundamental
- Price
- CPRI $19.72
- NVCR $17.77
- Analyst Decision
- CPRI Buy
- NVCR Strong Buy
- Analyst Count
- CPRI 11
- NVCR 4
- Target Price
- CPRI $26.18
- NVCR $37.50
- AVG Volume (30 Days)
- CPRI 4.0M
- NVCR 858.5K
- Earning Date
- CPRI 02-05-2025
- NVCR 05-01-2025
- Dividend Yield
- CPRI N/A
- NVCR N/A
- EPS Growth
- CPRI N/A
- NVCR N/A
- EPS
- CPRI N/A
- NVCR N/A
- Revenue
- CPRI $4,630,000,000.00
- NVCR $605,220,000.00
- Revenue This Year
- CPRI N/A
- NVCR $3.41
- Revenue Next Year
- CPRI N/A
- NVCR $9.24
- P/E Ratio
- CPRI N/A
- NVCR N/A
- Revenue Growth
- CPRI N/A
- NVCR 18.82
- 52 Week Low
- CPRI $18.52
- NVCR $11.70
- 52 Week High
- CPRI $45.77
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- CPRI 43.87
- NVCR 34.69
- Support Level
- CPRI $20.02
- NVCR $18.23
- Resistance Level
- CPRI $21.61
- NVCR $19.06
- Average True Range (ATR)
- CPRI 0.87
- NVCR 0.78
- MACD
- CPRI 0.05
- NVCR 0.03
- Stochastic Oscillator
- CPRI 48.15
- NVCR 1.38
About CPRI Capri Holdings Limited
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.